|
|
Article: ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors.
- Article from:
- Business Wire
- Article date:
- October 24, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented, for the first time, results of studies on its investigational, multi-targeted kinase inhibitor - AP24534 - showing anti-tumor activity in preclinical cancer models. These data were released at the EORTC-NCI-AACR (ENA) symposium on "Molecular Targets and Cancer Therapeutics" held in Geneva, Switzerland this week.
AP24534 demonstrated potent inhibition of selected kinase targets that control tumor growth and angiogenesis, notably all four receptors for fibroblast growth factors (FGFRs). The product candidate also inhibits the receptors for vascular endothelial growth factors (VEGFR), ...